---
document_datetime: 2025-01-08 16:26:34
document_pages: 18
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/renvela-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: renvela-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 11.1024126
conversion_datetime: 2025-12-31 02:44:33.571592
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Renvela

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| T/0066               | Transfer of Marketing Authorisation                | 03/12/2024                          | 19/12/2024                                  | SmPC, Labelling and PL           |           |
| IB/0065/G            | This was an application for a group of variations. | 20/09/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | to an approved stability protocol B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)   |            |            |                        | period/storage period or   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------|
| N/0064    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                            | 02/09/2024 | 19/12/2024 | PL                     |                            |
| IB/0063/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                         | 22/07/2024 | n/a        |                        |                            |
| IAIN/0062 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                  | 16/06/2023 | 30/08/2023 | SmPC, Labelling and PL |                            |
| IB/0061   | B.II.d.2.d - Change in test procedure for the finished                                                                                                                                                                                                                                                                                                                                                                                                                      | 02/06/2023 | n/a        |                        |                            |

<div style=\"page-break-after: always\"></div>

|           | - Other changes to a test procedure replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                 | product (including   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------|
| IB/0060/G | This was an application for a group of variations. B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method | 04/01/2023 | 30/08/2023 | Annex II and PL |                      |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.g - Change in the specification parameters and/or limits of an excipient - Where there is no monograph in the European/National Ph. for the excipient, a change in specification from in-house to a non-official/third country Ph. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a   |            |            |                       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|
| IB/0059/G | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.a.3.z - Changes in the composition (excipients) of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 29/07/2022 | 30/08/2023 | SmPC, Annex II and PL |

<div style=\"page-break-after: always\"></div>

|                    | B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary   |            |     |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/2697/ 202110 | Periodic Safety Update EU Single assessment - sevelamer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/06/2022 | n/a | PRAC Recommendation - maintenance |
| IA/0058            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 13/04/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0057   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                  | 14/02/2022   | n/a        |                        |                                                                                                                                                                     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0055    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                              | 12/11/2021   | 30/08/2023 | PL                     |                                                                                                                                                                     |
| IA/0054/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 02/09/2021   | n/a        |                        |                                                                                                                                                                     |
| WS/1854   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                  | 12/11/2020   | 18/02/2021 | SmPC, Labelling and PL |                                                                                                                                                                     |
| WS/1775   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated             | 17/04/2020   | n/a        |                        | Removal of identified or potential risks from the list of safety concerns as these risks are fully characterized and are followed up via routine pharmacovigilance. |

<div style=\"page-break-after: always\"></div>

|                    | by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |                        |                                                                                                                                           |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0052            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                            | 19/03/2020 | n/a        |                        |                                                                                                                                           |
| IG/1106            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                               | 15/01/2020 | 18/02/2021 | SmPC, Labelling and PL |                                                                                                                                           |
| PSUSA/2697/ 201810 | Periodic Safety Update EU Single assessment - sevelamer                                                                                                                                                                                                                                                                                                                                     | 27/06/2019 | 26/08/2019 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2697/201810. |
| WS/1560            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                           | 16/05/2019 | 26/08/2019 | SmPC, Labelling and PL |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| R/0046             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                  | 13/12/2018   | 20/02/2019   | SmPC, Annex II, Labelling and PL   |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------------------------------|
| IG/1003            | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                               | 20/12/2018   | 26/08/2019   | SmPC, Labelling and PL             |                                   |
| X/0039             | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                               | 26/07/2018   | 20/09/2018   | SmPC, Labelling and PL             |                                   |
| PSUSA/2697/ 201710 | Periodic Safety Update EU Single assessment - sevelamer                                                                                                                                                                                                                                                                                                                                  | 14/06/2018   | n/a          |                                    | PRAC Recommendation - maintenance |
| WS/1383            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                    | 07/06/2018   | n/a          |                                    |                                   |
| IG/0926/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.c.1.a - Change in immediate packaging of the AS | 06/06/2018   | n/a          |                                    |                                   |

<div style=\"page-break-after: always\"></div>

| II/0043   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                   | 17/05/2018   | n/a        |                        |                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------|
| WS/1332   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2 and 6.6 of the SmPC in order to include the use of food and beverage as an alternative to water for administration of sevelamer carbonate powder for oral suspension. The Package Leaflet is updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to revise the Annex A. C.I.4 - Change(s) in the SPC, Labelling or PL due to preclinical, clinical or pharmacovigilance | 22/02/2018   | 20/09/2018 | SmPC and PL            | new quality, data      |
| N/0040    | Minor change in labelling or package leaflet not SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 15/12/2017   | 20/09/2018 | Labelling and PL       | connected with the     |
| IG/0844   | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                                                                                                       | 22/09/2017   | 20/09/2018 | SmPC, Labelling and PL |                        |
| IG/0804/G | This was an application for a group of variations. the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 26/06/2017   | n/a        |                        | B.I.a.2.a - Changes in |

<div style=\"page-break-after: always\"></div>

|                    | the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             |                                                                                                                        |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------|
| WS/0965            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Extension of indication for Renvela 1.6 g and 2.4 g powder for oral suspension and Sevelamer carbonate Zentiva 2.4 g powder for oral suspension to include the control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area (BSA) of >0.75 m2) with chronic kidney disease. As a consequence, sections 4.2, 4.8 and 5.1 of the SmPC are updated in order to add information on posology and safety in paediatric patients and to reflect the results of the paediatric study. The Package Leaflet is updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 18/05/2017 | 26/06/2017 | SmPC and PL | Please refer to the Scientific Discussion of Renvela and Sevelamer carbonate Zentiva EMEA/H/C/WS0965.                  |
| PSUSA/2697/ 201610 | Periodic Safety Update EU Single assessment - sevelamer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 09/06/2017 | n/a        |             | PRAC Recommendation - maintenance                                                                                      |
| PSUSA/2697/ 201510 | Periodic Safety Update EU Single assessment - sevelamer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 23/06/2016 | 25/08/2016 | SmPC        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             | PSUSA/2697/201510.                                                                                                                                                                                                                                                                                 |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0867 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.5 of the SmPC regarding drug- drug interaction between sevelamer and proton pump inhibitors. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in section 4.8 of the SmPC of Renvela and Sevelamer carbonate Zentiva in order to harmonize the wording for all Sevelamer compounds. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 11/02/2016 | 25/08/2016 | SmPC and PL | Changes in gastric acidity with acid suppressants may potentially alter the efficacy of sevelamer HCL. During post- marketing experience, very rare cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer hydrochloride. |
| WS/0803 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                     | 19/11/2015 | n/a        |             |                                                                                                                                                                                                                                                                                                    |
| WS/0770 | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 01/10/2015 | 25/08/2016 | SmPC and PL |                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                    | Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data      |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2697/ 201410 | Periodic Safety Update EU Single assessment - sevelamer                                                                                                         | 11/06/2015 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| PSUV/0029          | Periodic Safety Update                                                                                                                                          | 04/12/2014 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IG/0418            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location | 11/04/2014 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0027             | Renewal of the marketing authorisation.                                                                                                                         | 23/01/2014 | 21/03/2014 | SmPC | The CHMP is agreement to renew the Marketing Authorisation Aplication for this product, one additional five-year renewal on the basis of pharmacovigilance grounds is requested by the CHMP. It remains unknown whether in human patients there could be a higher increase of urinary calcium after long-term treatment with sevelamer carbonate as compared to sevelamer hydrochloride. Non-clinical data suggest that long-term sevelamer carbonate may lead to a higher increase in urinary calcium as compared to what is observed with sevelamer hydrochloride. The relevance to humans of tumour formation in the urinary bladder in a rat carcinogenicity study with sevelamer hydrochloride is currently unknown. As the MAH did not perform the requested clinical study to assess this safety topic, an additional 5-year renewal is |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |    | deemed necessary to further evaluate this signal. Since this issue is still outstanding, the CHMP recommends that the MAH is requested to investigate in a new clinical study whether in human patients there could be a higher increase of urinary calcium after long-term treatment with sevelamer carbonate as compared to sevelamer hydrochloride. As a consequence of this outstanding issue, one additional five-year renewal on the basis of pharmacovigilance grounds is required.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0026    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 22/10/2013 | 21/03/2014 | PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IG/0332   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                        | 24/07/2013 | n/a        |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0023/G | This was an application for a group of variations. B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.III.2.a.2 - Change of specification(s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 24/05/2013 | n/a        |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IG/0283   | C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/03/2013 | n/a        |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                  |                                                                                                                                                                                                                                                                                                                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0021    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                               | 31/08/2012 | 21/03/2014 | PL                               |                                                                                                                                                                                                                                                                                                                                  |
| IB/0020   | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                    | 08/06/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                  |
| IB/0019   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                            | 31/05/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                  |
| N/0018    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                               | 12/04/2012 | 21/03/2014 | PL                               |                                                                                                                                                                                                                                                                                                                                  |
| IA/0017/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions | 28/03/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                  |
| WS/0188   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.4 of the SmPC in order to include precaution information regarding difficulties in                                                                                                                                                                           | 17/11/2011 | 22/12/2011 | SmPC, Annex II, Labelling and PL | The MAH was requested to perform a signal review on Renagel/Renvela for difficulties in swallowing/choking/aspiration due to obstruction of the airways or aspiration of tablet remnants in association with treatment with Renagel/Renvela. A total of seven cases were identified. Four of these patients recovered, for 2 the |

<div style=\"page-break-after: always\"></div>

| swallowing tablets and section 4.6. In order to add information on fertility. In addition, the list of local representatives in the Package Leaflet has been updated. Furthermore, the WSA proposed this opportunity to bring the PI in line with the latest QRD template version 8.0. Minor linguistic corrections have also been made to the Italian Annexes of Renvela. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   | outcomes are unknown, and 1 case was fatal (acute MI). In five cases, patients had to be hospitalized/hospitalization was prolonged and/or patients underwent bronchoscopy/endoscopy. The CHMP subsequently identified 12 cases in EudraVigilance on 17 March 2011. The CHMP requested the MAH to perform a cumulative review of cases of possible complications of swallowing Renagel/Renvela tablets, in particular focusing on the MedDRA PTs dysphagia, choking, aspiration, foreign body aspiration and oral administration complication. Swallowing is complex mechanical event, which can be influenced by a great many factors in Chronic Kidney Disease (CKD) patients. It is known for example that these patients often suffer from dysfunctional salivary glands. Furthermore, since hypertension is a frequent co-morbidity in CKD, water retention in the salivary gland's secretory process is not uncommon. Furthermore, concomitant conditions common in CKD patients (e.g. xerostomia, diabetic autonomic neuropathy, GERD and iron deficiency) can affect swallowing. CKD patients are generally also an older population with age related physiological changes such as laryngeal nerve dysfunction contributing to dysphagia and swallowing complications. The MAH performed a number of searches in different media to identify relevant case reports. The MAH's global safety database was queried for adverse events coding to specific Preferred Terms and MedDRA High Level Group Terms. In addition a search of medical literature was performed using Pubmed, OVID, EMBASE, and Biosis to identify any publications discussing choking on or difficulty   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |          | swallowing and sevelamer. In addition, both the Renagel Integrated Summary of Safety submitted with the Renagel MAA and the Renagel and Renvela post-approval safety studies were reviewed. Finally, The FDA Adverse Event Reporting System (AERS) database was also queried. During this query similar data regarding other drugs currently indicated for treatment of hyperphosphatemia in dialysis patients was also retained. The CHMP conclusion is that the MAH has taken adequate action in regards to these sporadic reports of swallowing difficulties by adding a precaution on the use of tablet in swallowing-impaired patients in the product SPC. There are no clinical nor quality related reason as to why Renvela/Renagel should be more difficult to swallow than   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0122 | To update the Detailed Description of the Pharmacovigilance System (DDPS) to version 9, to include a change in the major contractual arrangements. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD | 25/11/2011 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IG/0116 | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in                                                                                                                                                                                                                                                         | 28/10/2011 | 22/12/2011 | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | relation to another medicinal product of the same MAH                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             |                                                                                                                                                                                                                                                                                                                                                          |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0012   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                              | 23/09/2011 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                          |
| IA/0013/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 22/09/2011 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                          |
| IB/0010   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                             | 24/08/2011 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                          |
| II/0009   | C.I.4 - Variations related to significant modifications of the Summary of Product Characteristics due in particular to new quality, pre-clinical, clinical or pharmacovigilance data. C.I.4 - Variations related to significant modifications                                                                                                                                                                                                                            | 22/07/2010 | 06/09/2010 | SmPC and PL | Update of section 4.6 of the SPC to add information on fertility and to update to section 4.8 of the SPC to add pruritus, rash and intestinal perforation and consequential changes to section 4 of the PL. These proposed changes are to align the Renvela Product Information with the Renagel Product Information. In addition, the MAH has taken the |

<div style=\"page-break-after: always\"></div>

|         | of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                      |            |     |                        | opportunity to update the Product Information to align it with QRD template version 7.3 and to make minor changes to section 5.3 of the SPC and to section 3 of the PL.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0008 | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                        | 04/05/2010 | n/a |                        |                                                                                                                                                                           |
| IA/0007 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 04/05/2010 | n/a |                        |                                                                                                                                                                           |
| IB/0006 | IB_33_Minor change in the manufacture of the finished product                                                                       | 27/11/2009 | n/a |                        |                                                                                                                                                                           |
| IB/0005 | IB_33_Minor change in the manufacture of the finished product                                                                       | 05/10/2009 | n/a |                        |                                                                                                                                                                           |
| IB/0003 | IB_17_a_Change in re-test period of the active substance                                                                            | 02/09/2009 | n/a |                        |                                                                                                                                                                           |
| IA/0004 | IA_32_a_Change in batch size of the finished product - up to 10-fold                                                                | 27/08/2009 | n/a |                        |                                                                                                                                                                           |
| IB/0002 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                          | 31/07/2009 | n/a | SmPC, Labelling and PL |                                                                                                                                                                           |
| IB/0001 | IB_11_c_Change in batch size of active substance or intermediate - more than 10-fold                                                | 08/07/2009 | n/a |                        |                                                                                                                                                                           |